Total consumer spending on antacids (EphMRA classification groups: A02A1, A02A3, A02A4, and A02A6) in the retail segment for 2025 approached the RUB 14 billion mark (at retail prices, including VAT). Over the year, pharmacies sold 29 million packages. The growth rate compared to 2024 was recorded at 14.4% in monetary terms, while sales in packages increased by 5.2%. Notably, demand in this category has been steadily growing for several consecutive years. In 2024, the growth in packages reached 5.6% compared to 2023, and in 2023 it was recorded at +1.5%. During this period, the monetary sales volume consistently showed double-digit growth rates. Nevertheless, by the end of 2025, physical consumption of such products began to decline. In November and December, the long-term growth in packages was -0.7% and -1.6%, respectively, and in January 2026, demand fell by 5.5%.

In 2025, the average expenditure per capita (including Russia's new regions) in the heartburn remedy category reached RUB 92.8, a 14% increase over the previous year. During the year, each resident of our country purchased an average of about 0.19 packages of the relevant drugs. The main demand for antacids remains concentrated in Moscow, Moscow Oblast, and Saint Petersburg — these three federal subjects collectively account for nearly 27% of the monetary turnover and about 24% of sales in packages. However, in terms of per capita consumption of antacids, Moscow does not even rank in the Top 10 regions; it holds 11th place. Here, each resident purchased about 0.23 packages during 2025, spending approximately RUB 130 on them. Interestingly, first place belongs to Kamchatka Krai, where per capita consumption reaches 0.29 packages per person, with expenditure approaching RUB 163.

According to the database "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, first place in 2025 is held by Phosphalugel from Sanofi, with the product capturing 24.6% of the market. In second place, with a slight margin, is Almagel (Teva), accounting for 23.9% of the market. Rounding out the top three leading brands is Rennie from Bayer HealthCare with a 14.2% share. Notably, all these products demonstrate nearly identical growth dynamics of 14-15% in Russian currency. Interestingly, Almagel leads in sales in most federal subjects of the Russian Federation, but its total contribution to sales is outpaced by revenue from Phosphalugel in key regions.

The highest growth dynamics last year were shown by domestic products. It is noteworthy that sales of products from Russian pharmaceutical companies increased by 21% in physical terms and 38% in monetary terms. The top ten includes three domestic products. The largest volume among them was provided by Malvacid from AVVA Pharmaceutical, with ruble sales growing by 34% over the year. The highest growth was shown by Gasti from Renovation (+43%). Rounding out the top ten is another domestic product, Izhogoff from Evalar, with ruble sales volumes increasing by 19% over the year.

Table. TOP-10 Brand Names of Antacid Drugs (EphMRA groups: A02A1, A02A3, A02A4, and A02A6) on the Russian Retail Market (including online with delivery to consumers) in 2025